Latest News & Insights
Stay Up to Date with Our Community
Featured
Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and...
Capsida will also present data from its potential best-in-class programs for...
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration...
Neuron23 today announced the publication of a manuscript in the Proceedings of...
Data from the Phase 1 healthy volunteer study of NEU-411 will...
Financing led by funds managed by Blue Owl Capital; Senior Managing...
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in...
Capsida to receive a $40 million license payment and is eligible...
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s...
Data to be featured as oral and poster presentations at American...